Structure–Activity Relationship Analysis of Rhosin, a RhoA GTPase Inhibitor, Reveals a New Class of Antiplatelet Agents

Current antiplatelet therapies have several clinical complications and are mostly irreversible in terms of suppressing platelet activity; hence, there is a need to develop improved therapeutic agents. Previous studies have implicated RhoA in platelet activation. Here, we further characterized the le...

Descripción completa

Detalles Bibliográficos
Autores principales: Dandamudi, Akhila, Seibel, William, Tourdot, Benjamin, Cancelas, Jose A., Akbar, Huzoor, Zheng, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961652/
https://www.ncbi.nlm.nih.gov/pubmed/36835579
http://dx.doi.org/10.3390/ijms24044167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961652/
https://www.ncbi.nlm.nih.gov/pubmed/36835579
http://dx.doi.org/10.3390/ijms24044167

Ejemplares similares